cigna ppo glp 1 coverage Health insurer will stop covering GLP-1 weight loss drugs in its employee health plan Will Cigna Cover Ozempic®, Wegovy®,

Constitutional Delay of Growth and Puberty CDGP is the most common cause of short stature and delayed puberty in adolescents

The companys Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

This synergy maximizes the potential benefits of semaglutide GLP-1, helping individuals address the physiological drivers of hunger and optimize their response to food intake